He is the leader of the Myelodysplastic Syndrome and Myeloproliferative Disease Program at ISMMS, where he was the Principal Investigator for multiple national trials for those with MDS. He played a crucial role to finish the AZA-001 trial, which resulted in the approval of the 1st drug to address MDS, azacitidine (VIDAZA®).